Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Viking Therapeutics has reported promising phase I data for their oral weight loss drug, VK2735, with patients on 100-miligram doses losing 8.2% of their body weight after 28 days. Jefferies analyst Roger Song described the results as "class-leading." In other news, Biontech exceeded expectations in the third quarter due to the early approval of its updated COVID-19 ...